![[up]](/style/images/multi_up.png)
Up a levelGroup by: Item Type | Date
Jump to: Journal article
Number of items: 4.
Journal article
Fischer, L.; Mayer, A.; Irger, M.; Freysoldt, B.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. and Dreyling, M.
(2017):
CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB.
In: Haematologica, Vol. 102: p. 575
Hutter, G.; Zimmermann, Y.; Zoellner, A.; Irrgang, P.; Arnd, J.; Hiddemann, W. and Dreyling, M.
(2016):
Mode of action of different PI3K-inhibitors in mantle cell lymphoma.
In: Haematologica, Vol. 101: p. 271
Kvint, R.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. and Dreyling, M.
(2016):
High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL.
In: Oncology Research and Treatment, Vol. 39: pp. 153-154
Hutter, G.; Zimmermann, Y.; Bamopoulos, S. A.; Irger, M.; Hiddemann, W. and Dreyling, M.
(2016):
Synergistic effect of inhibition of multiple PI3K-isoforms due to the differential mode of action of single PI3K-isoform inhibitors in mantle cell lymphoma.
In: Oncology Research and Treatment, Vol. 39: p. 154